Andrew Tsai

Douglas Tsao

Jason Butler

Myles Minter

Thomas Shrader

- Minerva Neurosciences announced a financing of up to **$200 million** to advance roluperidone for the treatment of negative symptoms in patients with schizophrenia through a Phase 3 confirmatory trial, resubmission of its New Drug Application (NDA), and preparation for US commercial launch.  **[1598646_0001193125-25-245552_d28380dex991.htm:0]** 
- The financing includes **$80 million upfront** in exchange for Series A Convertible Preferred Stock, with up to an additional **$80 million** subject to the full exercise of Tranche A warrants, and a further **$40 million** contingent upon the cash exercise of Tranche B warrants upon achievement of a milestone event.  **[1598646_0001193125-25-245552_d28380dex991.htm:0]** 
- The company expects these proceeds to sufficiently fund its operations through the confirmatory Phase 3 trial for roluperidone and the resubmission of its NDA.  **[1598646_0001193125-25-245552_d28380dex991.htm:0]** 
- The closing of the private placement is expected on or about **October 23, 2025**, and will result in the appointment of up to **three additional directors** with significant schizophrenia clinical trial experience to Minerva's board.  **[1598646_0001193125-25-245552_d28380dex991.htm:0]**

Minerva Neurosciences (NERV)